Expression pattern of Notch intracellular domain (NICD) and Hes-1 in preneoplastic and neoplastic human oral squamous epithelium: Their correlation with c-Myc, clinicopathological factors and prognosis in Oral cancer

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Gokulan, Ravindran ^a,b   Halagowder, Devaraj ^a  

^a UNIVERSITY OF MADRAS   (India)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

c Myc; Cancer stem cells; Hes 1; Notch intracellular domain; Oral cancer

Indexed keywords

MYC PROTEIN; NESTIN; NOTCH INTRACELLULAR DOMAIN PROTEIN; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HES1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MYC PROTEIN, HUMAN; NES PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DYSPLASIA; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; AGED; EPITHELIUM; METABOLISM; MORTALITY; MOUTH TUMOR; PATHOLOGY; PRECANCER; PROTEIN TERTIARY STRUCTURE; REFERENCE VALUE; SURVIVAL;

AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; EPITHELIUM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NESTIN; PRECANCEROUS CONDITIONS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, NOTCH; REFERENCE VALUES; SURVIVAL ANALYSIS;

EID: 84904275495     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0126-1     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther. 2013;6:1249-59.
3. Nijman SMB. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011;585(1):1-6.
4. Dong Y, Li A, Wang J, Weber JD, Michel LS. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010;70:5465-74.
5. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010;16:3141-52.
6. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20:3427-36. (Pubitemid 32634350)
7. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154-7.
8. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3(7):770-81.
9. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011;208:1931-5.
10. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001;61:3200-5. (Pubitemid 32691976)
11. Kim SB, Chae GW, Lee J, Park J, Tak H, Chung JH, et al. Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. Cell Death Differ. 2007;14:982-91. (Pubitemid 46629836)
12. Ishida T, Hijioka H, Kume K, Miyawaki A, Nakamura N. Notch signaling induces EMT in OSCC cell lines in a hypoxic environment. Oncol Lett. 2013;6(5):1201-6.
13. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30:2307-13.
14. Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol. 2007;194:459-74. (Pubitemid 47471215)
15. Man CH, Wei-Man Lun S, Wai-Ying Hui J, To KF, Choy KW, Wing-Hung Chan A, et al. Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. J Pathol. 2012;226:471-81.
16. Ravindran G, Devaraj H. Aberrant expression of β-catenin and its association with ΔNp63, Notch 1 and clinicopathological factors in oral squamous cell carcinoma. Clin Oral Investig. 2012;16:1275-88.
17. Dang CV. MYC on the path to cancer. Cell. 2012;149:22.
18. Araki R, Hoki Y, Uda M, Nakamura M, Jincho Y, Tamura C, et al. Crucial role of C-Myc in the generation of induced pluripotent stem cells. Stem Cells. 2011;29:1362-70.
19. Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 2014;14:32.
20. Pindborg JJ, Reichart PA, Smith CJ, Van der Waal I. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. Berlin: Springer; 1997.
21. Minter HA, Eveson JW, Huntley S, Elder DJE, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res. 2003;9:1885.
22. Ravindran G, Devaraj H. Aberrant expression of CD133 and musashi-1 in preneoplastic and neoplastic human oral squamous epithelium and their correlation with clinicopathological factors. Head Neck. 2012;34:1129-35.
23. Hijioka H, Setoguchi T, Miyawaki A, Gao H, Ishida T, Komiya S, Nakamura N. Upregulation of Notch pathway molecules in oral squamous cell carcinoma. Int J Oncol. 2010;36:817-22.
24. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006;20:1028-42.
25. Zhang H, Wang X, Xu J, Sun Y. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014;110(9):2283-90.
26. Yoshida R, Nagata M, Nakayama H, Niimori-Kita K, Hassan W, Tanaka T, et al. The pathological significance of Notch1 in oral squamous cell carcinoma. Lab Invest. 2013;93:1068-81.
27. Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers. 2011;3:716-29.
28. Luo DH, Zhou Q, Hu SK, Xia YQ, Xu CC, Lin TS, et al. Differential expression of Notch1 intracellular domain and p21 proteins, and their clinical significance in gastric cancer. Oncol Lett. 2014;7(2):471-8.
29. Savill NJ, Sherratt JA. Control of epidermal stem cell clusters by Notch-mediated lateral induction. Dev Biol. 2003;258:141-53. (Pubitemid 36627662)
30. Sakamoto K, Fujii T, Kawachi H, Miki Y, Omura K, Morita K, Kayamori K, et al. Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms. Lab Invest. 2012;92(5):688-702.
31. Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy. Biochem Biophys Res Commun. 2014;444(4):670-5.
32. Kim HA, Koo BK, Cho JH, Kim YY, Seong J, Chang HJ, et al. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest. 2012;122(9):3248-59.
33. Peignon G, Durand A, Cacheux W, Ayrault O, Terris B, Laurent-Puig P, et al. Complex interplay between beta-catenin signalling and Notch effectors in intestinal tumourigenesis. Gut. 2011;60:166-76.
34. Shah NG, Trivedi TI, Tankshali RA, Goswami JV, Jetly DH, Shukla SN, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck. 2009;31:1544-56.
35. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013;19:1972-80.